Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04447833 Active, not recruiting - COVID Clinical Trials

Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome

ARDS-MSC-205
Start date: June 17, 2020
Phase: Phase 1
Study type: Interventional

This is an open label, dose escalating safety study of the advanced therapy investigational medicinal product (ATIMP) KI-MSC-PL-205, where patients diagnosed with SARS-CoV-2-induced severe acute respiratory distress syndrome (ARDS), according to the Berlin Definition, and who are on respirator/ventilator (used synonymously in this protocol) support due to respiratory insufficiency with or without concomitant circulatory problems, will be included and treated with a single dose of KI-MSC-PL-205.

NCT ID: NCT04447534 Completed - COVID Clinical Trials

Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19

Start date: June 23, 2020
Phase: Phase 3
Study type: Interventional

we want to investigate if zinc supplementation enhance the clinical efficacy of chloroquine in treatment of COVID-19.

NCT ID: NCT04447469 Completed - COVID Clinical Trials

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

Start date: July 27, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development phases (Phase 2 and Phase 3).

NCT ID: NCT04447235 Terminated - Cancer Clinical Trials

Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection

TITAN
Start date: July 23, 2020
Phase: Phase 2
Study type: Interventional

Ivermectin plus losartan as prophilaxy to severe events in patients with cancer with recent diagnosis of COVID-19

NCT ID: NCT04447222 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors

Start date: May 12, 2020
Phase:
Study type: Observational

This study uses questionnaires to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted health-related quality of life (HRQOL) and other areas such as COVID-19-specific psychological distress, disruptions to health care, finances and social interactions in cancer patients. The coronavirus disease 2019 (COVID-19) is an infectious disease that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The information learned from this study will guide the development of psychosocial programs to improve patient care and outcomes in cancer patients and survivors in the context of facing a global pandemic.

NCT ID: NCT04447144 Recruiting - Covid19 Clinical Trials

Nutritional Habits, and Coronavirus Disease 2019 (COVID-19) Outcome

Start date: June 1, 2020
Phase:
Study type: Observational

As of May 30th more than 23,000 cases of COVID -19 cases were confirmed in Egypt with total deaths of 913. Post viral entry, intense immune response against the virus with infiltration of monocytes and macrophages into alveolar cells with decreasing number of lymphocytes in peripheral blood along with reduced lymphocytes in lymphoid organs, hypercoagulability, thrombosis and multiple organ damage, The gut microbiota and immune homeostasis seem to have a back and forth relationship. Also, gut microbiota derived signals are known to tune the immune cells for pro and anti-inflammatory responses thereby affecting the susceptibility to various diseases. Healthy gut microbiome essentially could be pivotal in maintaining an optimal immune system to prevent an array of excessive immune reactions that eventually become detrimental to lungs and vital organ systems. Numerous studies have shown that the patient's nutritional status have a significant effect on an individual's immunity and over all health status and it has been suggested that nutritional deficiencies may predispose to severe forms of COVID-19 infections. Co-existing non-communicable chronic diseases (NCDs) in COVID-19 patients have been found to delay patients recovery and worsen their prognosis, the reason may be due to aggravated inflammatory pathology found in NCDs exacerbating COVID-19 infection. The aim of the study is to evaluate the role dietary habits among COVID-19 Egyptian patients and whether type of diet (Mediterranean or Western) will affect disease outcomes

NCT ID: NCT04447131 Completed - COVID-19 Clinical Trials

Effect of COVID-19 on Platelet Aggregation

Start date: April 29, 2020
Phase:
Study type: Observational

This is a mechanistic, observational, prospective, case and control study, to compare platelet aggregation, analyzed by Multiplate-ADP, in hospitalized patients diagnosed with COVID-19 versus healthy controls. Thus will be included 60 patients who present with respiratory symptoms within 72 hours of hospitalization and confirmation of the diagnosis of COVID-19 by laboratory method (RT -PCR and / or positive serology for SARS-CoV-2 - COVID group); this group will be compared to 60 healthy individuals (asymptomatic and with negative SARS-CoV-2 serology), matched by sex and age to the previous group.

NCT ID: NCT04446429 Completed - Prostate Cancer Clinical Trials

Anti-Androgen Treatment for COVID-19

Start date: October 21, 2020
Phase: N/A
Study type: Interventional

This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection

NCT ID: NCT04446377 Completed - COVID-19 Disease Clinical Trials

A Study of LAM-002A for the Prevention of Progression of COVID-19

Start date: July 15, 2020
Phase: Phase 2
Study type: Interventional

This is a clinical trial to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standards supportive care in an outpatient setting.

NCT ID: NCT04446338 Recruiting - Clinical trials for History of Covid-19, Seroprevalence

Immune Status SARS-CoV-2 in a Sample of a Tertiary Eye Health Centre

CovidImmunEye
Start date: May 13, 2020
Phase:
Study type: Observational

A sequential combination of different antibodies test against SARS-CoV-2 is evaluated. The protocol included a rapid test and several ELISA tests within a defined cohort of healthcare workers.